{
    "organizations": [],
    "uuid": "a9c53b406ac4eae803b134a6d3687645ad68a660",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-inovio-says-hiv-vaccine-maintained/brief-inovio-says-hiv-vaccine-maintained-immune-responses-one-year-after-start-of-trial-idUSASC0A29O",
    "ord_in_thread": 0,
    "title": "BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Inovio Pharmaceuticals Inc:\n* INOVIO HIV VACCINE, WHICH GENERATED NEAR 100% IMMUNE RESPONSES, SUSTAINED DURABLE MEMORY RESPONSES MEASURED ONE YEAR AFTER THE START OF CLINICAL TRIAL Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T20:19:00.000+03:00",
    "crawled": "2018-05-16T19:01:19.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "inovio",
        "pharmaceutical",
        "inc",
        "inovio",
        "hiv",
        "vaccine",
        "generated",
        "near",
        "immune",
        "response",
        "sustained",
        "durable",
        "memory",
        "response",
        "measured",
        "one",
        "year",
        "start",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}